Loading…
Reported covered position: Professional Staff Member, Senate Environment and Public Works Committee
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Dietary Supplement Innovation Act
Client: CHATTEM, INC D/B/A OPELLA · Firm: CHATTEM, INC D/B/A OPELLA
Nonprescription Drug Innovation Act (H.R.9774); dietary supplements; Generally Recognized as Safe (GRAS); Over the Counter Monograph User Fee Act (OMUFA); Generally Recognized as Safe and Effective (GRASE); HR.10336-Dietary Supplement Innovation Act; issues related to Rx to OTC Switch/PDUFA reauthorization.
Oral Health Products Inclusion Act
Client: CHATTEM, INC D/B/A OPELLA · Firm: CHATTEM, INC D/B/A OPELLA
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CHATTEM, INC D/B/A OPELLA via CHATTEM, INC D/B/A OPELLA
2026 · third_quarter · Q3
H.R.1219-To amend the Internal Revenue Code of 1986 to include over-the-counter oral healthcare products as qualified medical expenses which can be purchased with HSA and FSA funds.
Nonprescription Drug Innovation Act (H.R.9774); dietary supplements; Generally Recognized as Safe (GRAS); Over the Counter Monograph User Fee Act (OMUFA); Generally Recognized as Safe and Effective (GRASE); HR.10336-Dietary Supplement Innovation Act; issues related to Rx to OTC Switch/PDUFA reauthorization.
Source: Senate LDA
Issues related to the regulatory pathway for dietary supplements; issues related to the regulatory pathway for non-prescription drugs; H.R.1219, Oral Health Products Inclusion Act.
Oral Health Products Inclusion Act
Client: CHATTEM, INC D/B/A OPELLA · Firm: CHATTEM, INC D/B/A OPELLA
H.R.1219-To amend the Internal Revenue Code of 1986 to include over-the-counter oral healthcare products as qualified medical expenses which can be purchased with HSA and FSA funds.
To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
Client: CHATTEM, INC D/B/A OPELLA · Firm: CHATTEM, INC D/B/A OPELLA
Nonprescription Drug Innovation Act (H.R.9774); dietary supplements; Generally Recognized as Safe (GRAS); Over the Counter Monograph User Fee Act (OMUFA); Generally Recognized as Safe and Effective (GRASE); HR.10336-Dietary Supplement Innovation Act; issues related to Rx to OTC Switch/PDUFA reauthorization.
Over-the-Counter Monograph Drug User Fee Amendments
Client: CHATTEM, INC D/B/A OPELLA · Firm: CHATTEM, INC D/B/A OPELLA
H.R.4273 - Over-the-Counter Monograph User Fee Amendments; S.2292 - Over-the-counter Monograph User Fee Amendments; S.2529 - The Streamlining Market Access for Therapeutics OTC Act.
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: CHATTEM, INC D/B/A OPELLA · Firm: CHATTEM, INC D/B/A OPELLA
H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, S.2529 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, S.3122 - Better Food Disclosure Act of 2025
Over-the-Counter Monograph Drug User Fee Amendments
Client: CHATTEM, INC D/B/A OPELLA · Firm: CHATTEM, INC D/B/A OPELLA
H.R.4273 - Over-the-Counter Monograph User Fee Amendments; S.2292 - Over-the-counter Monograph User Fee Amendments; S.2529 - The Streamlining Market Access for Therapeutics OTC Act.
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.
Client: CHATTEM, INC D/B/A OPELLA · Firm: CHATTEM, INC D/B/A OPELLA
H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, S.2529 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, S.3122 - Better Food Disclosure Act of 2025
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.
Client: CHATTEM, INC D/B/A OPELLA · Firm: CHATTEM, INC D/B/A OPELLA
H.R.4273 - Over-the-Counter Monograph User Fee Amendments; S.2292 - Over-the-counter Monograph User Fee Amendments; S.2529 - The Streamlining Market Access for Therapeutics OTC Act.
H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, S.2529 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, S.3122 - Better Food Disclosure Act of 2025
Tariffs.
Illicit sale of OTCs on online retailer platforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHATTEM, INC D/B/A OPELLA via CHATTEM, INC D/B/A OPELLA
2026 · second_quarter · Q2
Organized retail theft; stolen goods on online marketplaces.
Issues related to the regulatory pathway for dietary supplements; issues related to the regulatory pathway for non-prescription drugs; H.R.1219, Oral Health Products Inclusion Act.
Tariffs
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CHATTEM, INC D/B/A OPELLA via CHATTEM, INC D/B/A OPELLA
2026 · first_quarter · Q1
OTC regulatory pathways - OMUFA and Rx to OTC Switch, Dietary Supplement regulation
Tariffs
Rx to OTC Switch (FDA) and chain of custody
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHATTEM, INC D/B/A OPELLA via CHATTEM, INC D/B/A OPELLA
2025 · fourth_quarter · Q4
H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, S.2529 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, S.3122 - Better Food Disclosure Act of 2025
Tariffs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHATTEM, INC D/B/A OPELLA via CHATTEM, INC D/B/A OPELLA
2025 · third_quarter · Q3
H.R.4273 - Over-the-Counter Monograph User Fee Amendments; S.2292 - Over-the-counter Monograph User Fee Amendments; S.2529 - The Streamlining Market Access for Therapeutics OTC Act.
Tariffs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHATTEM, INC D/B/A OPELLA via CHATTEM, INC D/B/A OPELLA
2025 · second_quarter · Q2
Regulatory pathways for OTC drugs and dietary supplements, including OMUFA and Rx to OTC switch.
Retail and cargo theft of medicines, counterfeit and diverted medicines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHATTEM, INC D/B/A OPELLA via CHATTEM, INC D/B/A OPELLA
2025 · first_quarter · Q1
Non-prescription drug issues. Monograph reauthorization. Rx to OTC switch. HSA/FSA.
Filing targets: HOUSE OF REPRESENTATIVES
CHATTEM, INC D/B/A OPELLA via CHATTEM, INC D/B/A OPELLA
2025 · first_quarter · RR
Healthcare policy for non-prescription drugs and dietary supplements, tax and trade.
Healthcare policy for non-prescription drugs and dietary supplements, tax and trade.
Healthcare policy for non-prescription drugs and dietary supplements, tax and trade.